Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection.
View/ Open
Date
1992Author
Tyndall, M
Agoki, E
Ombette, J
Slaney, LA
D'Costa, LJ
Plummer, FA
Plourde, PJ
Ndinya-Achola, JO
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Sexually transmitted diseases (STDs) have a significant adverse effect on reproductive and child health worldwide. The control of STDs such as gonorrhea is therefore an absolute priority. Cefixime, an oral third-generation cephalosporin with in vitro activity similar to that of ceftriaxone, may be an effective candidate for the treatment of gonorrhea. The efficacy of a single oral 400-mg dose of cefixime was compared with that of a single intramuscular 250-mg dose of ceftriaxone for the treatment of Neisseria gonorrhoeae urethritis in 190 men and cervicitis in 46 women in Nairobi, Kenya. A bacteriologic cure was recorded in 100% of 63 evaluatable patients treated with ceftriaxone and 118 (98%) of 121 evaluatable patients treated with cefixime. Cefixime, as a single oral dose, is an effective alternative for the treatment of uncomplicated gonococcal urethritis in men and cervicitis in women
URI
http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/1527431http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16972
Citation
J Infect Dis. 1992 Oct;166(4):919-22Publisher
Department of Medical Microbiology, University of Nairobi, Kenya.
Collections
- Faculty of Health Sciences (FHS) [10378]